Hormonal
Twelve-week treatment with the GLP-1 analogue liraglutide (1.8 mg/day) reduces hepatic de novo lipogenesis (DNL) and improves adipose tissue insulin sensitivity, thereby decreasing lipotoxicity in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
For patients with NASH, a 12-week course of liraglutide (titrated to 1.8 mg daily) has been shown to directly reduce the liver's production of new fat (DNL) and improve how fat tissue responds to insulin. This dual action reduces the toxic fat spill-over (lipotoxicity) that drives liver damage. While weight loss occurs, the study suggests direct metabolic benefits on the liver and fat tissue independent of weight change alone.
Liraglutide reduced hepatic DNL in-vivo (-1.26 vs. +1.30 %; p<0.05)... Liraglutide increased adipose tissue insulin sensitivity enhancing the ability of insulin to suppress lipolysis both globally... and specifically within subcutaneous adipose tissue (p<0.05).
Why this rating
Randomized, double-blind, placebo-controlled trial with mechanistic depth (clamps, isotopes, in vitro), though limited by small sample size (n=14).
Source
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Matthew J. Armstrong et al. · Journal of Hepatology · 2015
DOI 10.1016/j.jhep.2015.08.038
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →